Methods: Forty pregnant women, and 23 partners, attending Monash Health, in Melbourne, Australia, took part in focus groups or semi-structured interviews. All were given basic information on creatine. They considered under what circumstances they may take creatine, and whether dosing requirements or side-effects (weight gain) would be compliance barriers. One hundred health professionals also provided information on what they consider important when introducing a new therapy or supplement to their clinical practice. NVivo 12 was used to extract common themes and SPSS 25.0 for descriptive statistics.
EXPLORING PREGNANT WOMEN'S KNOWLEDGE AND ATTITUDES TOWARD DIETARY/NUTRITIONAL SUPPLEMENTATION IN PREGNANCY. DOES IT MATCH WITH HEALTH PROFESSIONALS' CURRENT CLINICAL
Methods: Forty women, and 23 partners, attending Monash Health, Melbourne, Australia, took part in focus groups or semistructured interviews; describing their knowledge, how they make choices and feel about dietary supplementation in pregnancy. One hundred health professionals, including share care GP's, midwives, obstetricians and trainee obstetricians, provided information via an online survey (REDCap) on their current clinical practice. NVivo 12 was used to extract themes from interviews and SPSS 25.0 for descriptive statistics.
Results: Overall, 87% of health professionals state they routinely ask about supplementation at first consultation. All women were taking a well-known brand supplement during pregnancy and knew about folic acid. All GP's stated they enquire about supplementation, which corresponded with all women taking a well-known brand supplement during pregnancy. In comparison 82% of Monash Health employees discussed supplementation at first visit. 50% of women took pre-pregnancy supplementation and 70% discussed "healthy eating".
Conclusions Background: Gastro-esophageal reflux (GER) is one of the most commonly diagnosed conditions in preterm infants. Treatment is often non-specific including positioning, feeding changes and pharmacologic agents. Due to lack of evidence of efficacy together with emerging evidence of significant harm, American Academy of Pediatrics strongly suggest that these gastric acid blockading agents should be used sparingly, if at all, in preterm infants. Hence a new pro-kinetic probiotic Lactobacillus Reuteri DSM17938 (Biogaia ® ) was introduced as an adjuvant treatment for GER at Nepean NICU in 2017.
Methods: This audit was a prospective and retrospective data collection using patient charts and electronic data base, to compare the demographic characteristics and key outcomes (omeprazole use and pre-specified GER attributed signs such as episodes of apnoea, bradycardia, feed associated desaturations, milky aspirates and vomiting) before (April 2016 -March 2017 vs. after introducing L. reuteri (August 2017-July 2018) in preterm (≤34 weeks) neonates. The institutional ethics committee approved the project and exempted it from need for written informed consent.
Results: Since introduction of L. reuteri, exclusive omeprazole use to treat GER cases saw a drop from 31/205 to 16/188, (p = 0.03). Reduction was more significant in preterm neonates <30 weeks from 51.6% to 24% (p = 0.01). Out of 54 preterm neonates treated with L.Reuteri, 77.3% showed improvement in pre-specified GER signs including episodes of apnoea, bradycardia, feed associated desaturations, milky aspirates and vomiting.
Conclusions: Probiotic Lactobacillus Reuteri (DSM17938) may be beneficial for treatment of GER and may reduce the use of proton pump inhibitors in high-risk preterm neonates. 
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